芪龙胶囊联合奥拉西坦治疗脑梗死后轻度认知障碍的临床研究  

Clinical Study on Qilong Capsule Combined with Oxiracetam in the Treatment of Mild Cognitive Impairment after Cerebral Infarction

作　　者：尉建辉[1] 高李[1] 李蒙 骆晓静 邢麟[2] WEI Jianhui;GAO LilLI Meng;LUO Xiaojing;XING Lin(Department of Neurology,Baoji Central Hospital,Baoji,Shaanxi 721000,China;Medical Branch,Baoji Vocational and Technical College,Baoji,Shaanxi 721000,China)

机构地区：[1]宝鸡市中心医院神经内科,陕西宝鸡721000 [2]宝鸡职业技术学院医学分院,陕西宝鸡721000

出　　处：《转化医学杂志》2024年第10期1769-1774,共6页Translational Medicine Journal

摘　　要：目的探究芪龙胶囊联合奥拉西坦对脑梗死后轻度认知障碍(MCI)的临床疗效,为中西医结合临床应用提供治疗方向。方法纳入2022年7月至2024年6月宝鸡市中心医院收治的脑梗死后MCI患者186例,采用随机数字法分为对照组和联合组,各93例。对照组给予奥拉西坦胶囊口服治疗,联合组给予奥拉西坦胶囊和芪龙胶囊口服治疗,2组均服用药物2个月。对2组患者治疗前后认知障碍、日常生活能力评估,对比2组患者治疗前后血清脑源性神经营养因子(BDNF)、神经元特异性烯醇化酶(NSE)、降钙素(PCT)、C反应蛋白(CRP)和血液中血浆黏度(PV)、红细胞比容(PCV)指标水平,以及2组患者治疗后的临床效果、不良反应和复发情况。结果治疗前,2组患者全科医生认知功能评估量表(GPCOG)、蒙特利尔认知评估(MoCA)、Barthel指数(BI)评分比较差异均无统计学意义(P>0.05);治疗后,2组患者GPCOG、MoCA、BI评分均高于本组治疗前(P<0.05),且联合组GPCOG、MoCA、BI评分均高于对照组(P<0.05)。治疗前联合组血清BDNF、NSE、PCT、CRP和血液中PV、PCV水平与对照组比较差异均无统计学意义(P>0.05),治疗后联合组血清BDNF水平高于对照组(P<0.05),NSE、PCT、CRP、PV、PCV水平均低于对照组(P<0.05);治疗后联合组的总有效率高于对照组(χ^(2)=6.226,P=0.013);联合组不良反应发生率与对照组比较差异无统计学意义(P>0.05);联合组复发率低于对照组(P<0.05)。结论芪龙胶囊联合奥拉西坦治疗脑梗死后轻度认知障碍效果明显,安全性好,复发率低。Objective To explore the clinical efficacy of Qilong Capsule combined with Oxiracetam in the treatment of mild cognitive impairment(MCI)after cerebral infarction,and to provide a treatment direction for the clinical application of integrated traditional Chinese and Western medicine.Methods A total of 186 patients with MCI after cerebral infarction who were admitted to Baoji Central Hospital from July 2022 to June 2024 were included and randomly divided into two groups with 93 patients in each group using the random number method.One group was designated as the control group,and the other was the combination group.The control group received Oxiracetam capsules,while the combination group received both Oxiracetam capsules and Qilong Capsules.Both groups underwent treatment for 2 months.The cognitive impairment of the two groups of patients was evaluated before and after treatment.The levels of brain-derived neurotrophic factor(BDNF),neuron-specific enolase(NSE),calcitonin(PCT),C-reactive protein(CRP)in serum,as well as plasma viscosity(PV)and hematocrit(PCV)in blood were compared between the two groups before and after treatment.Moreover,the clinical efficacy,occurrence and recurrence of adverse reactions of the two groups after treatment were also compared.Results Before treatment,there was no significant difference in the General Practitioner Assessment of Cognition(GPCOG),Montreal Cognitive Assessment(MoCA),and Barthel Index(BI)scores between the two groups(P>0.05).After treatment,GPCOG,MoCA,and Instrumental Activities of Daily Living(IADL)scores in both groups were significantly higher than their respective baseline scores(P<0.05),and the GPCOG,MoCA,and BI scores in the combination group were significantly higher than those in the control group(P<0.05).Before treatment,there were no significant differences in serum levels of BDNF,NSE,PCT,CRP,PV,PCV between the two groups(P>0.05).After treatment,the serum BDNF level in the combination group was significantly higher than that in the control group(P<0.05),while th

关 键 词：脑梗死 轻度认知功能障碍 芪龙胶囊 奥拉西坦 

分 类 号：R743.33[医药卫生—神经病学与精神病学]